2022 Annual Meeting | Controversies in Neurology Plenary Session

Date Saturday 04/02/22

Time 09:15 AM - 11:15 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Plenary Session

Director(s) Amy R. Brooks-Kayal, MD, FAAN, Martinson K. Arnan, MD, FAAN

Topic(s) General Neurology

Learning Objectives This session features experts discussing the most current and controversial issues in neuroscience. Tune in for a scholarly debate between two expert speakers, each advocating for one side of a single topic, followed by a rebuttal.

CME Available 2.00 CME credits

Program Materials Program Evaluations

Event Timeline
09:15 AM - 09:49 AM PDT	Speaker	Should Patients with a Single Unprovoked Seizure be Evaluated and Treated as if They Have Epilepsy? Anteneh M. Feyissa, MD, MSc, FAAN, Gregory D. Cascino, MD, FAAN
09:49 AM - 10:23 AM PDT	Speaker	Aducanumab: To Prescribe or Not Prescribe David S. Knopman, MD, FAAN, Alireza Atri, MD, PhD
10:23 AM - 10:58 AM PDT	Speaker	Should Anticoagulation be Restarted After Cerebral Hemorrhage for Secondary Stroke Prevention in AFib? Edip M. Gurol, MD, Kevin N. Sheth, MD, FAAN

Faculty Disclosures
Amy R. Brooks-Kayal, MD, FAAN	Dr. Brooks-Kayal has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for ABPN. Dr. Brooks-Kayal has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. Dr. Brooks-Kayal has stock in Johnson and Johnson. The institution of Dr. Brooks-Kayal has received research support from NINDS.
Martinson K. Arnan, MD, FAAN	Dr. Arnan has nothing to disclose.
Anteneh M. Feyissa, MD, MSc, FAAN	Dr. Feyissa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis.
David S. Knopman, MD, FAAN	Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Edip M. Gurol, MD	The institution of Dr. Gurol has received research support from NIH/NINDS. The institution of Dr. Gurol has received research support from Boston Scientific Corporation. The institution of Dr. Gurol has received research support from AVID (a wholly owned subsidiary of Eli Lilly). The institution of Dr. Gurol has received research support from Pfizer.
Kevin N. Sheth, MD, FAAN	Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Alireza Atri, MD, PhD	Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Prothena. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Atri has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lunbeck. The institution of Dr. Atri has received research support from National Institute of Aging (NIA). The institution of Dr. Atri has received research support from AZ Department of Health Services. The institution of Dr. Atri has received research support from Gates Ventures. The institution of Dr. Atri has received research support from Multiple companies, universities & consortia for contracted clinical trials to institution. The institution of Dr. Atri has received research support from Washington University in St. Louis. The institution of Dr. Atri has received research support from Foundation for NIH. The institution of Dr. Atri has received research support from ACTC/NIH. Dr. Atri has received publishing royalties from a publication relating to health care.
Gregory D. Cascino, MD, FAAN	Dr. Cascino has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for International League Against Epilepsy . Dr. Cascino has received intellectual property interests from a discovery or technology relating to health care. Dr. Cascino has received publishing royalties from a publication relating to health care. Dr. Cascino has received publishing royalties from a publication relating to health care.